Intercept Slides As Analyst Calls CymaBay Drug 'True Contender' After Data
July 17, 2017 at 16:33 PM EDT
Shares of Intercept Pharmaceuticals are sliding after H.C. Wainwright analyst Ed Arce raised his price target for its competitor CymaBay Therapeutics following data from the company's Phase 2 study of seladelpar in primary biliary cholangitis.
